Fig. 2From: A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraineOverall mean change from baseline in the number of monthly migraine headache days. *P < .05; **P < .01. Overall least squares (LS) mean change from baseline in the number of migraine headache days for patients who were treated with monthly open-label injections of galcanezumab 120 mg or 240 mgBack to article page